Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an increase in accidental drug-related deaths year over year The ...

The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression. Johnson & Johnson said patients who use ...

Nandita Vijayasimha, Bengaluru Thursday, February 6, 2025, 08:00 Hrs [IST] ...

(www.corstasis.com), a clinical-stage MedTech pharmaceutical company developing innovative, practical therapies for fluid ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...